Prospects for Novartis' ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3 trial in wet age-related macular degeneration (AMD). On the plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results